{"id":"https://openalex.org/W4310127304","doi":"https://doi.org/10.1182/blood-2022-160179","title":"Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013","display_name":"Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310127304","doi":"https://doi.org/10.1182/blood-2022-160179"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-160179","doi":"https://doi.org/10.1182/blood-2022-160179","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-160179","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002643270","display_name":"Naseema Gangat","orcid":"https://orcid.org/0000-0002-9104-6172","observed_orcids":["https://orcid.org/0000-0002-9104-6172"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naseema Gangat","raw_affiliation_strings":["1Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080965667","display_name":"Kebede H. Begna","orcid":"https://orcid.org/0000-0003-2730-8593","observed_orcids":["https://orcid.org/0000-0003-2730-8593"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kebede H. Begna","raw_affiliation_strings":["2Divison of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Divison of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008422091","display_name":"Aref Al\u2010Kali","orcid":"https://orcid.org/0000-0002-0824-3715","observed_orcids":["https://orcid.org/0000-0002-0824-3715"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aref Al-Kali","raw_affiliation_strings":["1Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084606047","display_name":"William J. Hogan","orcid":"https://orcid.org/0000-0002-5841-4105","observed_orcids":["https://orcid.org/0000-0002-5841-4105"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William J. Hogan","raw_affiliation_strings":["1Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085360755","display_name":"Mark Robert Litzow","orcid":"https://orcid.org/0000-0002-9816-6302","observed_orcids":["https://orcid.org/0000-0002-9816-6302"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark R. Litzow","raw_affiliation_strings":["1Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024612499","display_name":"Animesh Dev Pardanani","orcid":"https://orcid.org/0000-0002-9084-4148","observed_orcids":["https://orcid.org/0000-0002-9084-4148"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Animesh Pardanani","raw_affiliation_strings":["1Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016216479","display_name":"Ayalew Tefferi","orcid":"https://orcid.org/0000-0003-4605-3821","observed_orcids":["https://orcid.org/0000-0003-4605-3821"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayalew Tefferi","raw_affiliation_strings":["1Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1330342723"],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.3716,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.61719432,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":95},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"3945","last_page":"3946"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9629999995231628},{"id":"https://openalex.org/keywords/jak2-inhibitors","display_name":"JAK2 inhibitors","score":0.9649999737739563},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/fedratinib","display_name":"fedratinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/momelotinib","display_name":"momelotinib","score":1.0},{"id":"https://openalex.org/keywords/pacritinib","display_name":"pacritinib","score":0.8840000033378601},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.6320000290870667},{"id":"https://openalex.org/keywords/predictors-of-treatment-response","display_name":"predictors of treatment response","score":0.7419999837875366},{"id":"https://openalex.org/keywords/spleen-response","display_name":"spleen response","score":0.6610000133514404},{"id":"https://openalex.org/keywords/jak2-mutation","display_name":"JAK2 mutation","score":0.5600000023841858},{"id":"https://openalex.org/keywords/calr-mutation","display_name":"CALR mutation","score":0.8830000162124634},{"id":"https://openalex.org/keywords/mpl-mutation","display_name":"MPL mutation","score":0.9340000152587891},{"id":"https://openalex.org/keywords/asxl1-mutation","display_name":"ASXL1 mutation","score":0.8080000281333923},{"id":"https://openalex.org/keywords/driver-mutations","display_name":"driver mutations","score":0.39800000190734863},{"id":"https://openalex.org/keywords/post-polycythemia-vera-myelofibrosis","display_name":"post-polycythemia vera myelofibrosis","score":0.8100000023841858},{"id":"https://openalex.org/keywords/post-essential-thrombocythemia-myelofibrosis","display_name":"post-essential thrombocythemia myelofibrosis","score":0.9779999852180481},{"id":"https://openalex.org/keywords/long-term-treatment-outcomes","display_name":"long-term treatment outcomes","score":0.6169999837875366},{"id":"https://openalex.org/keywords/clinical-trial-patients","display_name":"clinical trial patients","score":0.3840000033378601}],"concepts":[{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.9570766687393188},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8872379064559937},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7785792946815491},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.554753839969635},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4959615170955658},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4418218731880188},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3826477527618408},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34857630729675293},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.15791496634483337}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-160179","doi":"https://doi.org/10.1182/blood-2022-160179","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-160179","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4313546167","https://openalex.org/W2297842098","https://openalex.org/W4294715477","https://openalex.org/W2769686372","https://openalex.org/W4225643117","https://openalex.org/W2622547803","https://openalex.org/W1465072532","https://openalex.org/W2768722269","https://openalex.org/W2545615751","https://openalex.org/W3096039995"],"abstract_inverted_index":{"Introduction":[0],"Currently,":[1],"ruxolitinib,":[2,60,434],"fedratinib":[3,89,166,317,343,382,595],"and":[4,16,48,53,81,107,127,172,210,238,245,255,277,283,313,330,347,375,392,437,444,506,516,519,559,583,586,597],"pacritinib":[5],"are":[6],"three":[7,535],"FDA-approved":[8],"JAK2":[9,29,65,174,190,326,388,439,555,576],"inhibitors":[10],"used":[11],"for":[12,367,550],"palliation":[13],"of":[14,51,144,181,215,248,265,290,299,308,334,362,370,396,424,499,508,575,590,599],"splenomegaly":[15],"constitutional":[17,256],"symptoms":[18],"in":[19,55,123,191,194,197,203,207,212,221,297,331,360,393,451,484,517,581,587],"patients":[20,57,74,111,149,249,272,303,366,417,453,552],"with":[21,75,120,150,286,304,316,342,378,420,433,497,609],"myelofibrosis.":[22],"However,":[23],"a":[24,179,261,368],"durable":[25,562],"survival":[26,54,423,481,563],"benefit":[27,564],"from":[28],"inhibitor":[30,66,147,175,327,389,440,556,577],"therapy":[31],"remains":[32],"unclear.":[33],"In":[34,593],"the":[35,101,134,225,332,394,403,533,561,588],"current":[36,71,544],"study,":[37],"our":[38],"primary":[39,76],"objective":[40],"was":[41,219,233,295,358,431,482,570,579],"to":[42,133,478],"retrospectively":[43,113],"compare":[44],"long-term":[45,547],"treatment":[46,288],"outcomes":[47],"identify":[49],"predictors":[50],"response":[52,129,294,306],"myelofibrosis":[56,77,551],"treated":[58,553],"on":[59,86,353,407,539,554],"fedratinib,":[61,435],"momelotinib":[62,92,169,322,379,436],"or":[63,95,324,386],"BMS-911543":[64,96,325,387,438],"clinical":[67,98,557],"trials.":[68],"Methods":[69],"The":[70,543],"study":[72,545],"includes":[73],"(PMF),":[78],"post-polycythemia":[79],"vera":[80],"post-essential":[82],"thrombocythemia":[83],"MF":[84,151],"enrolled":[85],"ruxolitinib":[87,163,320,345,384],"(NCT00509899),":[88],"(NCT00631462,":[90],"NCT01420770),":[91],"(NCT00935987,":[93],"NCT01236638),":[94],"(NCT01236352)":[97],"trials":[99,558],"at":[100,178],"Mayo":[102],"Clinic":[103],"between":[104],"October":[105],"2007":[106],"July":[108,124],"2013.":[109],"Study":[110],"were":[112,130,228,281,455],"recruited":[114],"after":[115],"institutional":[116],"review":[117],"board":[118],"approval":[119],"follow-up":[121],"updated":[122],"2022.":[125],"Spleen":[126,293],"anemia":[128,520,584,610],"assessed":[131],"according":[132],"revised":[135],"IWG-MRT":[136],"criteria":[137],"(Blood,":[138],"2013).":[139],"ResultsPatient":[140],"characteristics:":[141],"A":[142],"total":[143],"183":[145],"JAK":[146],"na\u00efve":[148],"(median":[152],"age":[153],"65":[154],"years,":[155,446,491,504,514,525,529],"range":[156],"34-89;":[157],"58%":[158],"males,":[159],"60%":[160],"PMF)":[161],"received":[162],"(n=50,":[164],"27%),":[165],"(n=23,":[167],"13%),":[168],"(n=79,":[170],"43%)":[171],"BMS":[173],"(n=31,":[176],"17%)":[177],"median":[180,262,287,305,369,421],"27":[182,361],"months":[183,310,372],"following":[184],"diagnosis.":[185],"Driver":[186],"mutation":[187],"profile":[188],"included":[189,201],"80%,":[192],"CALR":[193],"11%,":[195],"MPL":[196],"5%;":[198],"other":[199],"mutations":[200,336,349,398,510,601,607],"ASXL1":[202,335,348,500,600],"58/124":[204],"(47%),":[205],"SRSF2":[206,397,509,591,606],"16/84":[208],"(19%)":[209],"IDH1/2":[211],"2/74":[213],"(3%)":[214],"evaluable":[216,302],"patients.":[217],"Karyotype":[218],"abnormal":[220],"97":[222],"(53%);":[223],"among":[224],"latter,":[226],"53%":[227],"unfavorable.":[229],"DIPSS-plus":[230,485],"risk":[231,487],"distribution":[232],"intermediate-1":[234,486],"(15%),":[235],"intermediate-2":[236],"(46%)":[237],"high":[239],"(39%).":[240],"166":[241,300],"(91%),":[242],"66":[243,363],"(36%)":[244],"136":[246],"(74%)":[247],"demonstrated":[250],"palpable":[251],"splenomegaly,":[252],"transfusion-dependent":[253,365],"anemia,":[254],"symptoms,":[257],"respectively.":[258],"Response:":[259],"At":[260,412],"follow":[263],"up":[264],"3.7":[266,425],"years":[267,426],"(0.1-14.4":[268],"years),":[269],"178":[270],"(97%)":[271],"have":[273,418],"discontinued":[274],"therapy.":[275],"3":[276],"5-year":[278],"discontinuation":[279],"rates":[280],"77%":[282],"92%,":[284],"respectively":[285],"duration":[289,307],"17":[291],"months.":[292],"achieved":[296,359],"83":[298],"(50%)":[301],"22":[309,452],"(2-132":[311],"months)":[312],"more":[314,376],"likely":[315,377],"(83%)":[318],"vs":[319,338,344,381,400,457,463,470,502,512,523,527],"(32%),":[321],"(47%)":[323,364],"(62%)":[328],"(p=0.0003)":[329],"absence":[333,498,507,589,598],"(58%":[337],"37%,":[339],"p=0.02).":[340],"Treatment":[341],"(p=0.04)":[346],"(p=0.01)":[350],"remained":[351,537],"significant":[352,538],"multivariable":[354,408,540],"analysis.":[355,541],"Transfusion":[356],"independence":[357],"14":[371],"(6-82":[373],"months),":[374],"(51%)":[380],"(13%),":[383],"(30%)":[385],"(44%)":[390],"(p=0.15)":[391],"presence":[395],"(75%":[399],"31%,":[401],"p=0.02),":[402,515],"latter":[404,534],"retained":[405],"significance":[406],"analysis":[409,476],"(p=0.04).":[410],"Survival:":[411],"last":[413],"follow-up,":[414],"149":[415],"(81%)":[416],"died":[419],"overall":[422],"(3/5/10-year":[427],"survival;":[428],"60%/41%/16%).":[429],"Survival":[430,569],"similar":[432],"(4,":[441],"4.4,":[442],"3.5":[443,513],"5.9":[445],"respectively,":[447,495,532],"p=0.33)":[448],"but":[449,578],"longer":[450],"that":[454],"transplanted":[456,460],"those":[458],"not":[459,571],"(not":[461],"reached":[462],"3.3":[464],"years;":[465],"p<0.001,":[466],"5/10-year":[467],"survival,":[468],"91%45%":[469],"47%19%)":[471],"(Figure":[472],"1).":[473],"On":[474],"univariate":[475],"limited":[477],"non-transplanted":[479],"patients,":[480],"superior":[483,580],"(7,":[488],"3.5,":[489],"2.9":[490],"intermediate-1,":[492],"2,":[493],"high-risk,":[494],"p=0.001),":[496],"(3.8":[501],"2.8":[503],"p=0.003)":[505],"(3.7":[511],"spleen":[518,582,603],"responders":[521,585],"(5.1":[522],"2.3":[524],"p<0.0001)(3.5":[526],"2.1":[528],"p=":[530],"0.003)":[531],"variables":[536],"Conclusions":[542],"provides":[546],"outcome":[548],"data":[549],"underscores":[560],"conferred":[565],"by":[566,573],"allogeneic":[567],"transplantation.":[568],"influenced":[572],"type":[574],"mutations.":[592],"addition,":[594],"use":[596],"predicted":[602],"response,":[604],"while":[605],"correlated":[608],"response.":[611],"Figure":[612],"1View":[613,616],"largeDownload":[614,617],"PPTFigure":[615],"PPT":[618],"Close":[619],"modal":[620]},"counts_by_year":[{"year":2023,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}